Published in Dig Dis Sci on September 11, 2011
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One (2015) 0.86
Ethanol extract of Cordyceps militaris grown on germinated soybeans attenuates dextran-sodium-sulfate- (DSS-) induced colitis by suppressing the expression of matrix metalloproteinases and inflammatory mediators. Biomed Res Int (2013) 0.82
Ethanol Extract of Antrodia camphorata Grown on Germinated Brown Rice Suppresses Inflammatory Responses in Mice with Acute DSS-Induced Colitis. Evid Based Complement Alternat Med (2013) 0.82
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res (2014) 0.78
Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis (2013) 0.75
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One (2017) 0.75
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol (2009) 2.53
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther (2007) 1.62
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology (1999) 1.61
Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.45
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis (2010) 1.32
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol (2005) 1.27
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther (2010) 1.18
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol (2000) 1.03
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis (2010) 1.02
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol (2010) 0.93
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther (2010) 0.90
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther (2010) 0.84
Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis (2009) 0.78
A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther (2010) 0.77
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet (2002) 2.74
Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol (2008) 2.74
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One (2012) 1.66
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther (2006) 1.63
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol (2009) 1.58
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci (2014) 1.44
Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol (2008) 1.42
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ (2013) 1.18
Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr (2002) 1.11
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Probiotics for recurrent Clostridium difficile disease. J Med Microbiol (2005) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology (2008) 1.04
Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer (2010) 1.01
Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc (2010) 1.00
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis (2015) 0.99
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology (2013) 0.97
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A (2013) 0.97
Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol (2006) 0.96
Inflammatory bowel disease and environmental influences. Gastroenterol Clin North Am (2002) 0.95
Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev (2008) 0.95
Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis (2013) 0.93
Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med (2013) 0.92
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis (2013) 0.92
Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.92
Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis (2010) 0.92
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev (2011) 0.91
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology (2014) 0.88
Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. Dig Dis Sci (2009) 0.87
Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol (2012) 0.87
Growth factors as treatment options for intestinal inflammation. Ann N Y Acad Sci (2006) 0.86
Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis (2012) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Upper endoscopy in patients with acute myocardial infarction and upper gastrointestinal bleeding: results of a decision analysis. Dig Dis Sci (2008) 0.84
Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol (2005) 0.84
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys (2007) 0.82
Treatment of intra-abdominal abscesses in Crohn's disease: a nationwide analysis of patterns and outcomes of care. Dig Dis Sci (2013) 0.82
Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol (2011) 0.81
Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 0.80
Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population. AJR Am J Roentgenol (2010) 0.79
Secular trends in patients diagnosed with Barrett's esophagus. Dig Dis Sci (2009) 0.79
What is the clinical importance of small polyps with regard to colorectal cancer screening? Nat Clin Pract Gastroenterol Hepatol (2006) 0.78
Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. Inflamm Bowel Dis (2017) 0.77
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) (2013) 0.77
Responsiveness of the testing morbidities index in colonoscopy. Value Health (2013) 0.77
Esophageal capsule endoscopy for Barrett's esophagus screening: a hard pill to swallow? Clin Gastroenterol Hepatol (2007) 0.76
Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis (2015) 0.76
Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2009) 0.75
How to value technological innovation: a proposal for determining relative clinical value. Gastroenterology (2012) 0.75
Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. Inflamm Bowel Dis (2016) 0.75
Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way? J Clin Gastroenterol (2016) 0.75
Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. Radiology (2016) 0.75
Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome. Inflamm Bowel Dis (2014) 0.75